PRECIGEN, INC. (PGEN): Results of Operations and Financial Condition
PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflects accelerating commercial momentum and bro
How this was made
The 30-second read
Why it matters
Key trading takeaways are (1) PAPZIMEOS commercial sales driving Q2 profitability, (2) FDA seven-year market exclusivity, (3) permanent CMS J-code J3404 effective April 1, 2026 supporting reimbursement workflow, and (4) a stated cash runway to cash-flow break-even by end of 2026 based on current cash plus expected PAPZIMEOS proceeds.
Market read
The filing provides fresh, decision-relevant datapoints on revenue, profitability, exclusivity, and reimbursement mechanics, which can re-rate near-term demand expectations and funding risk for PGEN.
What to watch
The article does not quantify treated-patient conversion rates from hub enrollment to actual dosing, nor does it provide detailed guidance for Q3/Q4 revenue trajectory beyond the cash-flow break-even statement.
Background
This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 covering Precigen’s second quarter 2026 financial results and business updates for PAPZIMEOS and the AdenoVerse pipeline.
Ticker impact
Precigen reports Q2 2026 results with PAPZIMEOS net revenue of $53.1M, profitability, and cash expected to fund operations to cash-flow break-even by end of 2026.
Likely supportive for the stock on any market reaction to profitability and funding runway, with upside sensitivity to continued PAPZIMEOS demand and EMA MAA progress.
The filing is a primary disclosure (8-K) with concrete revenue, cash runway, and regulatory/reimbursement milestones. However, it provides limited forward guidance detail beyond funding break-even timing, so magnitude of price impact is uncertain.
Market effects
Reinforces the commercial traction narrative for precision oncology/immunotherapy launches, especially where reimbursement infrastructure (J-code) and exclusivity reduce adoption friction.
Primarily US-focused (FDA exclusivity, CMS J-code, insured lives coverage), with Europe as a secondary optionality via EMA MAA review.
EMA review validation and planned global expansion create a pathway for future ex-US revenue optionality, but timing is not specified beyond year-end pipeline updates.
Counterpoint
Profitability may be heavily influenced by accounting treatment changes around PAPZIMEOS manufacturing costs, so cash generation and sustainability should be validated in subsequent quarters.
Key entities
- issuerPrecigen, Inc.
Commercial-stage biopharmaceutical company reporting Q2 2026 results and PAPZIMEOS adoption milestones.
- productPAPZIMEOS (zopapogene imadenovec-drba)
FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis (RRP), with Q2 net revenue of $53.1M and seven-year market exclusivity.
- regulatorFDA
Granted seven-year market exclusivity for PAPZIMEOS.
- reimbursement authorityCMS
Assigned permanent J-code J3404 effective April 1, 2026 for PAPZIMEOS reimbursement.
- regulatorEMA
Validated and is reviewing the MAA for PAPZIMEOS in adults with RRP.
